Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 23, 2017
Prometic enters into binding letter of intent to secure USD $80 million (CAD $100 million) line of credit from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.
Laval, Qc , Oct. 23, 2017 /CNW Telbec/ -Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic") announced today that it has entered into a binding letter of ...
October 23, 2017
Reata Announces First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of Friedreich’s Ataxia
IRVING, Texas, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”) today announced the enrollment of the first patient in the ...
October 23, 2017
Soleno Therapeutics Regains Compliance with NASDAQ Listing Requirements
REDWOOD CITY, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
October 23, 2017
Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017
PASADENA, Calif.--(BUSINESS WIRE) -- Arrowhead Pharmaceuticals Inc. (ARWR) today presented data from studies demonstrating promising preclinical safety and efficacy of ARO-AAT, a second-generation investigational medicine for ...
October 23, 2017
Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD) Meeting
PALO ALTO, Calif., Oct. 23, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (EIGR) today announced positive interim 24-week data with pegylated interferon lambda (Lambda) in the ...
October 23, 2017
Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017
LIVONIA, Mich., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
October 23, 2017
VBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company Headquarters
TEL AVIV, Israel, Oct. 23, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT) announced today the opening of its new gene therapy manufacturing plant in Modiin, ...
October 23, 2017
AIT Therapeutics Announces the Last Patient Has Completed Dosing in its Phase 2 NO-NTM Clinical Trial for Patients Suffering from Nontuberculous Mycobacteria (NTM) Abscessus
NEW YORK, Oct. 23, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the ...
October 23, 2017
BrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn® Technology for Parkinson's Disease And ALS
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 23, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has ...
October 20, 2017
DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint
CUPERTINO, Calif., Oct. 19, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today reported that PERSIST, the Phase 3 clinical trial for POSIMIR® (SABER®-Bupivacaine), did not meet its ...
October 20, 2017
Ignyta Announces Pricing of Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (RXDX) ("Ignyta"), a biotechnology company focused on precision medicine in oncology, today announced the pricing of an underwritten public offering of ...
October 20, 2017
VBL Therapeutics Announces Orphan Drug Designation for VB-111 in Europe
TEL AVIV, Israel, Oct. 20, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
October 20, 2017
Final Results of Albireo’s Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting® 2017
BOSTON, Oct. 20, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
October 20, 2017
Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference
HOPKINTON, Mass., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
October 20, 2017
HTG Molecular Diagnostics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Tuesday, November 7
TUCSON, Ariz., Oct. 20, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents and services for molecular profiling applications, today ...
October 20, 2017
AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier (IMPD) Submission
BROOKLYN, N.Y., Oct. 20, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc. (AZRX) (“AzurRx” or the “Company”), announced the submission of an Investigational Medicinal Product Dossier ...
October 20, 2017
Reata Announces Late-Breaking Presentation of Primary Results From Phase 2 CARDINAL Study at the American Society of Nephrology Kidney Week 2017 Annual Meeting
IRVING, Texas, Oct. 20, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”) announced that the primary efficacy and safety data from the ...
October 19, 2017
High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds
EMERYVILLE, Calif. and BREST, France, Oct. 19, 2017 (GLOBE NEWSWIRE) -- The Dravet Syndrome European Federation and Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies ...
October 19, 2017
Prometic Receives Priority Review Status From Health Canada for Plasminogen (Ryplazim™)
LAVAL, QC , Oct. 19, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced that Health Canada has granted priority review status ...
October 19, 2017
Galmed Pharmaceuticals to Host Key Opinion Leader Meeting on Non-Alcoholic Steato-Hepatitis (NASH)
TEL AVIV, Israel, Oct. 19, 2017 /PRNewswire/ -- Galmed Pharmaceuticals, Inc. (GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for ...
Page 96 of 128